Systematic review and meta-analysis of Pimavanserin and Volinanserin in Schizophrena treatment

Simple item page
dc.contributor.advisorMoreno, Georgina
dc.contributor.committeeMemberMalin, David
dc.contributor.committeeMemberWard, Christopher
dc.creatorVargas Cruz, Nylev Suann
dc.date.accessioned2022-08-03T16:45:39Z
dc.date.available2022-08-03T16:45:39Z
dc.date.created2022-05
dc.date.issued2022-05-12
dc.date.submittedMay 2022
dc.date.updated2022-08-03T16:45:40Z
dc.description.abstractSchizophrenia is a severe mental disorder that affects 1% of the population. Despite its low prevalence, it is ranked among the top fifteen leading causes of disability worldwide. Antipsychotics targeting serotonergic receptors, specifically 5-HT2A receptors, are being developed for schizophrenia treatment and continue to show promise. Pimavanserin and Volinanserin are two such atypical antipsychotics that are highly selective towards the 5-HT2A receptor. In this study, we performed a systematic review and meta-analysis of Volinanserin (MDL-100907) and Pimavanserin (ACP-103) to evaluate the effectiveness of these drugs in the treatment of schizophrenia. A literature search was performed using Pub-Med, ClinicalTrials.gov, and Cochrane databases. Our search strategy consisted of the following strings: Pimavanserin or ACP-103 and Volinanserin or MDL-100907 and Schizophrenia or Schizophrenia spectrum. Based on comparable outcomes of measurement (i.e., PANSS, SGI, KSS, DAI-10), Pimavanserin is a safe adjunctive treatment. However, there is not enough data to conclude efficacy. These results provide additional support for 5-HT2A as a key component for the treatment of schizophrenia. Continued research is needed on the efficacy of Pimavanserin, Volinanserin, and other drugs that target 5-HT2A receptors in the treatment of schizophrenia.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/10657.1/2675
dc.language.isoen
dc.subjectschizophrenia, atypical antipsychotics, pimavanserin, volinanserin
dc.titleSystematic review and meta-analysis of Pimavanserin and Volinanserin in Schizophrena treatment
dc.typeThesis
dc.type.materialtext
thesis.degree.grantorUniversity of Houston-Clear Lake
thesis.degree.levelMasters
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
VARGASCRUZ-MASTERSTHESIS-2022.pdf
Size:
930.27 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.87 KB
Format:
Plain Text
Description:
Download
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
4.46 KB
Format:
Plain Text
Description:
Download

Collections

Theses and Dissertations
College of Human Sciences and Humanities Projects, Theses, and Dissertations